| Literature DB >> 30405849 |
Tao Wang1, Jingjing Hou2, Shuo Jian1, Qicong Luo1, Jie Wei3, Zengpeng Li4, Xuegang Wang1, Peide Bai1, Bo Duan1, Jinchun Xing1, Jianchun Cai2.
Abstract
MicroRNAs (miRNAs) are important regulators and associated with the development of many different types of cancer, including gastric cancer. However, their pathophysiologic role and their relevance to tumorigenesis, invasion and metastasis are still unknown. In our current study, we performed microRNA array and found that 28 of miRNAs were differentially expressed in INF type of gastric cancer. Among 28 miRNAs, miR-29b was one of the most significantly down-regulated miRNA. Further bioinformatics analysis showed that MMP2 was a potential target of miR-29b. Interestingly, luciferase analysis showed that miR-29b negatively regulates MMP2 by binding with the miRNA response element (MRE) on the 3'UTR of MMP2. In addition, overexpression of miR-29b significantly decreased the mRNA and protein level of MMP2 and the activity of MMP2 to suppress gastric cancer cell migration. Moreover, lentivirus mediated overexpression of miR-29b dramatically suppressed the ability of BGC823 cells to form colonies in vitro and their ability to develop tumor in vivo in nude mice. Finally, our qPCR and western blot analysis showed that miR-29b was significantly reduced in clinical gastric cancer tissue, whereas MMP2 protein was significantly up-regulated, suggesting that this aberrant down-regulation of miR-29b might be associated with the abnormal regulation of MMP2 and the development of gastric cancer. Significant apparent was also found between miR-29b expression and TNM staging, lymph node status, tumor differentiation and Ming classification. Together, our data suggest an important regulatory role of miR-29b in the development of gastric cancer. Thus, miR-29b and MMP2 might be important diagnostic or therapeutic targets for human tumor diseases.Entities:
Keywords: MMP2; gastric cancer; micorRNA-29b; tumor migration
Year: 2018 PMID: 30405849 PMCID: PMC6216010 DOI: 10.7150/jca.26263
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Summary of differentially expressed miRNAs in INF type of gastric cancer compared with normal gastric tissues. *, P values were calculated using Significance Analysis of Microarrays in the Bioconductor package. P value < 0.05 was considered statistically significant.
| miRNAs | Fold change | |
|---|---|---|
| hsa-miR-29c | 0.162 | 0.0005 |
| hsa-miR-29b | 0.285 | 0.028 |
| hsa-miR-1184 | 0.398 | 0.006 |
| hsa-miRPlus-E1241 | 0.417 | 0.031 |
| hsa-miR-647 | 0.427 | 0.039 |
| hsa-miRPlus-E1018 | 0.528 | 0.002 |
| hsa-miRPlus-F1026 | 0.569 | 0.047 |
| hsa-miR-187* | 0.578 | 0.029 |
| hsa-let-7d | 0.579 | 0.038 |
| hsa-miR-124* | 0.614 | 0.009 |
| hsa-miR-185* | 0.615 | 0.006 |
| hsa-miR-150 | 0.629 | 0.035 |
| hsv1-miR-H7* | 0.641 | 0.041 |
| hsa-miR-650 | 0.693 | 0.033 |
| hsa-miR-602 | 0.739 | 0.035 |
| ebv-miR-BHRF1-1 | 0.757 | 0.024 |
| hsa-miRPlus-F1028 | 0.766 | 0.015 |
| hsa-miRPlus-E1093 | 0.797 | 0.016 |
| hsa-miR-589* | 0.814 | 0.041 |
| hsa-miRPlus-E1133 | 0.82 | 0.025 |
| hsa-miR-1204 | 0.851 | 0.048 |
| hsa-miR-548d-5p | 3.214 | 0.013 |
| hsa-miR-130b* | 2.722 | 0.036 |
| hsa-miRPlus-E1245 | 2.656 | 0.045 |
| hsa-miR-21* | 2.137 | 0.017 |
| hsa-miR-671-5p | 2.034 | 0.005 |
| hsa-miR-516b | 1.328 | 0.025 |
| hsa-miR-320d | 1.09 | 0.006 |
Figure 1miR-29b regulate MMP2 post-transcriptionally. (A) Sequence alignment showing that miR-29a/b/c-3p are evolutionarily conserved in human. (B) Bioinformatic prediction of miR-29b recognition elements on the human MMP2-3' UTR. Analyses were performed with either the mirRanda or TargetScan algorithms. (C) Transfection of miR-29 precusor significantly increased miR-29b expression while reduced the MMP2 mRNA expression level in BGC823 cells. (D) miR-29b regulates MMP2 by interacting with the 3' UTR of MMP2. (E and F) Overexpression of miR-29b significantly repressed MMP2 protein expression in BGC823 and MGC803 gastric cancer cells. BGC823 or MGC803 cells were transfected with pLV-MIR29b or control plasmid as indicated. Data are represented as the mean ± SEM (n = 3). **, p < 0.01; ***, p < 0.001.
Figure 2Effects of overexpression of miR-29b in BGC823 and MGC803 cells on cell migration. For wound-healing assay, BGC823 or MGC803 cells were seeded and transfected with pLV-MIR29b or the control plasmid. 24, 48 or 72 hours after the transfection, wound healing was recorded in photographs. For the transwell migration assay, approximately 2.5 × 104 transfected cells were plated in the upper chamber for transwell assay and the rest of the cells were collected for Western blot analysis. Data are expressed as the mean ± SEM (n = 3). ***, p < 0.001. (A and B) Overexpression of miR-29b significantly suppressed BGC823 and MGC803 cell migration as determined in a wound-healing assay. (C and D) Overexpression of miR-29b significantly suppressed cell migration as determined in a transwell assay.
Figure 3Overexpression of miR-29b significantly inhibits GC cell colony formation (A and B) The effect of miR-29b on the colony formation of BGC823 cells. (C) Time-dependent growth of xenograft tumor tissues in nude mice. Lentivirus infected BGC823 cells were harvested and suspended in PBS and then inoculated subcutaneously (~1 × 106 cells/100 ml/mouse) into the right side of the posterior flank of 6-week-old nude mice. (D) Tumor growth in nude mice 25 days after injection with LV-MIR-ctrl- or LV-MIR29b -infected cells. (E) Comparison of tumor weights. (F) Altered expression of MMP2 and PCNA in dissected tumor tissues. Data are expressed as the mean ± SEM (n = 3). NS, not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 4Analysis of miR-29b and MMP2 expression in GC samples. (A) miR-29b expression was significantly down-regulated in human GC tissues. (B) Western blot demonstrating the protein expression level of MMP2 in GC tissues. (C) Inverse correlation between the expression of miR-29b and the expression of MMP2 protein in 15 pairs of GC clinical samples. Abbreviations: T, GC tissue; N, adjacent noncancerous gastric tissue; U6 mRNA were calibrated for qPCR analysis; α-tubulin was used as a control for protein loading.
Correlation between the expression of miR-29b and the clinicopathological features of 49 GC patients. P value < 0.05 was considered statistically significant.
| Clinicopathological features | % | miR-29b | |||
|---|---|---|---|---|---|
| Gender | M | 35 | 71.4 | 0.512±0.241 | 0.929 |
| F | 14 | 28.6 | 0.441±0.102 | ||
| Age | <60 | 25 | 51 | 0.434±0.167 | 0.574 |
| ≥60 | 24 | 49 | 0.527±0.179 | ||
| Maximum diameter of mass | <5cm | 22 | 44.9 | 0.405±0.19 | 0.22 |
| ≥5cm | 27 | 55.1 | 0.52±0.18 | ||
| TNM stage | Ⅰ, Ⅱ | 14 | 28.6 | 0.645±0.295 | 0.034 |
| Ⅲ, Ⅳ | 35 | 71.4 | 0.43±0.14 | ||
| Degree of differentiation | Low | 23 | 46.9 | 0.43±0.16 | 0.036 |
| Mid | 17 | 34.7 | 0.45±0.23 | ||
| High | 9 | 18.4 | 0.6±0.32 | ||
| Lymph node status | ≥1 | 40 | 71.6 | 0.44±0.17 | 0.027 |
| 0 | 9 | 18.4 | 0.6±0.465 | ||
| Ming classification | EXP | 34 | 69.4 | 0.522±0.142 | 0.028 |
| IFN | 15 | 30.6 | 0.383±0.224 | ||